NEW YORK (GenomeWeb) – Illumina said today that it would invest $100 million in a new venture capital firm, Illumina Venture.

Nicholas Naclerio, formerly Illumina's senior vice president of corporate and venture development, is launching the investment firm.

Illumina will be the majority limited partner in the first fund and its $100 million investment will be callable over 10 years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.

Sep
07
Sponsored by
PerkinElmer

This webinar will address improvements in the library prep workflow for small RNA sequencing in serum and plasma.

Sep
20
Sponsored by
Ion Torrent

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep
21
Sponsored by
Roche

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
26
Sponsored by
PerkinElmer

This webinar will describe a protocol and proof-of-principle experiments for Cellular Indexing of Transcriptome and Epitopes by Sequencing (CITE-seq).